International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

Young Scientist Abstracts

2017

Microbial Biotransformation of Five Pyrrolidinophenone-type Psychoactive Substances in Wastewater and a Wastewater Isolated Pseudomonas putida Strain
https://www.ncbi.nlm.nih.gov/pubmed/28092435

Mardal M, Bischoff M, Ibáñez M, Ruffing U, Hernández F, Meyer MR.

Drug Test Anal. 2017 doi: 10.1002/dta.2165.

Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS.
https://www.ncbi.nlm.nih.gov/pubmed/27933361

Michely JA, Brandt SD, Meyer MR, Maurer HH.

Anal Bioanal Chem. 2017 Feb;409(6):1681-1695.

Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MSn, and LC-HR-MS/MS approaches.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Caspar+AT%2C+Brandt+SD%2C+Stoever+AE%2C+Meyer+MR%2C+Maurer+HH

Caspar AT, Brandt SD, Stoever AE, Meyer MR, Maurer HH

J Pharm Biomed Anal. 2017 Feb 5;134:158-169.

The effect of an antibiotic checklist on length of hospital stay and appropriate antibiotic use in adult patients treated with intravenous antibiotics: a stepped wedge cluster randomised trial.
https://www.ncbi.nlm.nih.gov/pubmed/28159671

van Daalen FV, Prins JM, Opmeer BC, Boermeester MA, Visser CE, van Hest RM, Branger J, Mattsson E, van de Broek MF, Roeleveld TC, Karimbeg AA, Haak EA, van den Hout EC, van Agtmael MA, Hulscher ME, Geerlings SE.

Clin Microbiol Infect. 2017 Jan 31. [Epub ahead of print]

LC-MS/MS Method for Quantitative Analysis of Clozapine, Its Major Metabolites (Norclozapine and Clozapine N-Oxide), and Trazodone in Serum.

Merrigan SD, Powers JL, Johnson-Davis KL.

Mass Spectrometry Applications to the Clinical Laboratory. Palm Springs, CA. January 22-26, 2017.

Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.
https://www.ncbi.nlm.nih.gov/pubmed/27100373

Brandt SD, Kavanagh PV, Dowling G, Talbot B, Westphal F, Meyer MR, Maurer HH, Halberstadt AL.

Drug Test Anal. 2017 Jan;9(1):115-126.

Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques.
https://www.ncbi.nlm.nih.gov/pubmed/26888521

Mardal M, Kinyua J, Ramin P, Miserez B, Van Nuijs AL, Covaci A, Meyer MR.

Drug Test Anal. 2017 Jan;9(1):106-114.

2016

Determination of Antidepressants in Hair via UHPLC-MS/MS as a Complementary Informative Tool for Clinical and Forensic Toxicological Assessments.
https://www.ncbi.nlm.nih.gov/pubmed/27851687

Ramírez Fernández Mdel M, Wille SM, Hill V, Samyn N.

Ther Drug Monit 2016 Dec;38 (6): 751-760., PMID:27851687

Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.
https://www.ncbi.nlm.nih.gov/pubmed/27559840

Loustaud-Ratti V, Maynard M, Thevenon S, Pradat P, Rousseau A, Alain S, Deny P, Gagnieu M-C, Tran A, Dao T, Silvain C, Lunel-Fabiani F, Picard N, Zublena I, Marquet P, Trepo C.

Ther Drug Monit. 2016 Dec;38(6):684–92.

The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence
https://www.ncbi.nlm.nih.gov/pubmed/27607458

Ott C, Mahfoud F, Schmid A, Ewen S, Toennes SW, Meyer MR, Helfer AG, Maurer HH, Ditting T, Veelken R, Zivanovic I, Uder M, Böhm M, Schmieder RE.

J Hypertens. 2016 Dec;34(12):2475-2479.

Measuring biomarkers in wastewater as a new source of epidemiological information: Current state and future perspectives.
https://www.ncbi.nlm.nih.gov/pubmed/28038971

Gracia-Lor E, Castiglioni S, Bade R, Been F, Castrignanò E, Covaci A, González-Mariño I, Hapeshi E, Kasprzyk-Hordern B, Kinyua J, Lai FY, Letzel T, Lopardo L, Meyer MR, O'Brien J, Ramin P, Rousis NI, Rydevik A, Ryu Y, Santos MM, Senta I, Thomaidis NS, Veloutsou S, Yang Z, Zuccato E, Bijlsma L

Environ Int. 2016. doi: 10.1016/j.envint.2016.12.016.

Challenges concerning new psychoactive substance detection in oral fluid
http://www.sciencedirect.com/science/article/pii/S2352007816302293

Wille SM, Eliaerts J, Di Fazio V, Samyn N.

Toxac doi: 10.1016/j.toxac.2016.12.004

New psychoactive substances in a drugged driving population: Preliminary results.
http://www.em-consulte.com/article/1098692/new-psychoactive-substances-in-a-drugged-driving-p

Nachon-Phanithavong M., Wille SM, Richeval C.,Di Fazio V., Samyn N., Humbert L., Gaulier JM, Allorge D.

Toxac doi : 10.1016/j.toxac.2016.12.002

Neonate with Mycoplasma hominis meningoencephalitis given moxifloxacin.
https://www.ncbi.nlm.nih.gov/pubmed/27641775

Wildenbeest JG, Said I, Jaeger B, van Hest RM, van de Beek D, Pajkrt D.

Lancet Infect Dis. 2016 Nov;16(11):e261-e266.

Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical  Outcomes and Nephrotoxicity in Liver Transplant Recipients.
https://www.ncbi.nlm.nih.gov/pubmed/27653228

Debette-Gratien M, Woillard J-B, Picard N, Sebagh M, Loustaud-Ratti V, Sautereau D, Samuel D, Marquet P.

Transplantation. 2016 Oct;100(10):2129–37.

A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
https://www.ncbi.nlm.nih.gov/pubmed/27454665

Mathew SK, Mathew BS, Neely MN, Naik GS, Prabha R, Jacob GG, K S, Fleming DH.

Ther Drug Monit. 2016 Oct;38(5):593-9.

New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics.
https://www.ncbi.nlm.nih.gov/pubmed/27665567

Meyer MR.

Arch Toxicol. 2016 Oct;90(10):2421-44.

Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS.
https://www.ncbi.nlm.nih.gov/pubmed/26810883

Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR.

Drug Test Anal. 2016 Oct;8(10):1039-1048

Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in  renal transplant patients.
https://www.ncbi.nlm.nih.gov/pubmed/27402191

Billat P-A, Ossman T, Saint-Marcoux F, Essig M, Rerolle J-P, Kamar N, Rostaing L, Kaminski H, Fabre G, Otyepka M, Woillard J-B, Marquet P, Trouillas P, Picard N.

Pharmacol Res. 2016 Sep;111:501–8.

High-resolution mass spectrometry in toxicology: current status and future perspectives.
https://www.ncbi.nlm.nih.gov/pubmed/2736937

Maurer HH, Meyer MR.

Arch Toxicol. 2016 Sep;90(9):2161-72.

Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches
https://www.ncbi.nlm.nih.gov/pubmed/27372715

Richter LH, Kaminski YR, Noor F, Meyer MR, Maurer HH.

Anal Bioanal Chem. 2016 Sep;408(23):6283-94.

3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques.
https://www.ncbi.nlm.nih.gov/pubmed/27372715

Mardal M, Miserez B, Bade R, Portolés T, Bischoff M, Hernández F, Meyer MR.

J Pharm Biomed Anal. 2016 Sep 5;128:485-95.

What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?
https://www.ncbi.nlm.nih.gov/pubmed/27320963

Wagmann L, Meyer MR, Maurer HH.

Toxicol Lett. 2016 Sep 6;258:55-70.

Metabolic Patterns of Drugs and Drug Metabolites Observed in Urine, Serum or Plasma.

Wu F, Slawson MH, Johnson-Davis KL.

American Association for Clinical Chemistry (AACC). Philadelphia, PA. July.

Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices - Where do we stand today?
https://www.ncbi.nlm.nih.gov/pubmed/27237833

Meyer MR, Maurer HH.

Anal Chim Acta. 2016 Jul 13;927:13-20.

Therapeutic drug monitoring of anti-infective agents in critically ill patients.
https://www.ncbi.nlm.nih.gov/pubmed/27018631

Jager NG, van Hest RM, Lipman J, Taccone FS, Roberts JA.

Expert Rev Clin Pharmacol. 2016 Jul;9(7):961-79.

LC-HR-MS/MS standard urine screening approach: Pros and cons of automated on-line extraction by turbulent flow chromatography versus dilute-and-shoot and comparison with established urine precipitation.
https://www.ncbi.nlm.nih.gov/pubmed/27381570

Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 doi: 10.1016/j.jchromb.2016.06.036.

Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans?
https://www.ncbi.nlm.nih.gov/pubmed/27328899

Schaefer N, Helfer AG, Kettner M, Laschke MW, Schlote J, Ewald AH, Meyer MR, Menger MD, Maurer HH, Schmidt PH

Drug Test Anal. 2016 Jun 22.

LDTD-MS/MS Method for Quantitative Analysis of Four Immunosuppressant Drugs in Whole Blood and Cost Analysis Comparison to LC-MS/MS.

Merrigan SD, Slawson M, Auger S, and Johnson-Davis KL.

American Society for Mass Spectrometry. San Antonio, TX. June 5-9, 2016

Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes.
https://www.ncbi.nlm.nih.gov/pubmed/27071765

Meyer MR, Bergstrand MP, Helander A, Beck O.

Anal Bioanal Chem. 2016 May;408(13):3571-91.

Therapeutic Drug Monitoring of Everolimus: A Consensus Report.
https://www.ncbi.nlm.nih.gov/pubmed/26982492

Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, Brunet M, Budde K, Barten MJ, De Simone P, Wieland E, Lopez OM, Masuda S, Seger C, Picard N, Oellerich M, Langman LJ, Wallemacq P, Morris RG, Thompson C, Marquet P.

Ther Drug Monit. 2016 Apr;38(2):143–69.

Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation.
https://www.ncbi.nlm.nih.gov/pubmed/26418704

Shipkova M, Lopez OM, Picard N, Noceti O, Sommerer C, Christians U, Wieland E.

Ther Drug Monit. 2016 Apr;38 Suppl 1:S80–92.

Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
https://www.ncbi.nlm.nih.gov/pubmed/26469711

Picard N, Bergan S, Marquet P, van Gelder T, Wallemacq P, Hesselink DA, Haufroid V.

Ther Drug Monit. 2016 Apr;38 Suppl 1:S57–69.

Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ
https://www.ncbi.nlm.nih.gov/pubmed/26977997

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, Lopez-Hoyos M, Barten MJ, Bergan S, Picard N, Millan Lopez O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M.

Transplantation. Ther Drug Monit. 2016 Apr;38 Suppl 1:S1–20.

Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
https://www.ncbi.nlm.nih.gov/pubmed/26700738

Veillon P, Fouchard-Hubert I, Larrey D, Dao MT, D’alteroche L, Boyer-Darrigand N, Picard N, Le Guillou-Guillemette H, Saulnier P, Ducancelle A, Loustaud-Ratti V, Lunel-Fabiani F.

J Interferon Cytokine Res. 2016 Mar;36(3):204–14.

Genetic polymorphisms in the immune response: A focus on kidney transplantation.
https://www.ncbi.nlm.nih.gov/pubmed/26171975

Stojanova J, Pouche L, Picard N.

Clin Biochem. 2016 Mar;49(4-5):363–76.

A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation.
https://www.ncbi.nlm.nih.gov/pubmed/26894651

Pouche L, Koitka M, Stojanova J, Woillard J-B, Monchaud C, Villeneuve C, Essig M, Abraham J, Le Meur Y, Rerolle J-P, Kamar N, Rostaing L, Merville P, Gandia P, Bouchet S, Petersen B-S, Marquet P, Picard N.

Pharmacogenomics. 2016 Mar;17(4):375–91.

New challenges and promises in solid organ transplantation pharmacogenetics: the  genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs.
https://www.ncbi.nlm.nih.gov/pubmed/26799749

Pouche L, Stojanova J, Marquet P, Picard N.

Pharmacogenomics. 2016 Feb;17(3):277–96.

Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology.
https://www.ncbi.nlm.nih.gov/pubmed/26924594

Meyer GM, Maurer HH, Meyer MR.

Bioanalysis. 2016;8(5):457-81.

Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?
https://www.ncbi.nlm.nih.gov/pubmed/26538506

Billat P-A, Woillard J-B, Essig M, Sauvage F-L, Picard N, Alain S, Neely M, Marquet P, Saint-Marcoux F.

J Antimicrob Chemother. 2016 Feb;71(2):484–9.

Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis.
https://www.ncbi.nlm.nih.gov/pubmed/28038961

Hodiamont CJ, Juffermans NP, Bouman CS, de Jong MD, Mathôt RA, van Hest RM.

Int J Antimicrob Agents. 2017 Feb;49(2):204-211.

Development of Antibiotic Resistance during Simulated Treatment of Pseudomonas aeruginosa in Chemostats.
https://www.ncbi.nlm.nih.gov/pubmed/26872140

Feng Y, Hodiamont CJ, van Hest RM, Brul S, Schultsz C, Ter Kuile BH.

PLoS One. 2016 Feb 12;11(2):e0149310.

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.
https://www.ncbi.nlm.nih.gov/pubmed/26599973

Dinger J, Woods C, Brandt SD, Meyer MR, Maurer HH.

Toxicol Lett. 2016 Jan 22;241:82-94.

2015

LC-MS/MS method for determination of teriflunomide, over a 40,000-fold dynamic range using overlapping calibrators
http://www.ncbi.nlm.nih.gov/pubmed/25525756

Rule GS, Rockwood AL, Johnson-Davis KL

Ther Drug Monit. 2015 Aug;37(4):472-8.

A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays.
http://www.ncbi.nlm.nih.gov/pubmed/25596249

McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG.

Am J Clin Pathol. 2015 Feb;143(2):234-40.

Everolimus method comparison between Waters MassTrak™ Immunosuppressants XE (IUO) kit and an in-house laboratory developed LC-MS/MS method in renal transplant patients.
http://www.ncbi.nlm.nih.gov/pubmed/25696007

Johnson-Davis KL, Juenke JM, Thomas RL, Bradshaw T.

Ann Clin Lab Sci. 2015 Winter;45(1):27-31.

Ethyl Glucuronide Positivity Rate in a Pain Management Population.
http://www.ncbi.nlm.nih.gov/pubmed/26324207

Johnson-Davis KL, Slawson MH.

J Anal Toxicol. 2015 Nov;39(9):686-90.

One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry.
http://www.ncbi.nlm.nih.gov/pubmed/26342055

Marin SJ, Doyle K, Chang A, Concheiro-Guisan M, Huestis MA, Johnson-Davis KL

J Anal Toxicol. 2016 Jan-Feb;40(1):37-42. Epub 2015 Sep 4.

A Retrospective Analysis of Urine Drugs of Abuse Immunoassay True Positive Rates at a National Reference Laboratory.
http://www.ncbi.nlm.nih.gov/pubmed/26668238

Johnson-Davis KL, Sadler AJ, Genzen JR

J Anal Toxicol. 2016 Mar;40(2):97-107. Epub 2015 Dec 13

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.
http://www.ncbi.nlm.nih.gov/pubmed/26599973

Dinger J, Woods C, Brandt SD, Meyer MR, Maurer HH.

Toxicol Lett. 2016 Jan 22;241:82-94. Epub 2015 Nov 17.

Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance.
http://www.ncbi.nlm.nih.gov/pubmed/26485463

Ewen S, Cremers B, Meyer MR, Donazzan L, Kindermann I, Ukena C, Helfer AG, Maurer HH, Laufs U, Grassi G, Böhm M, Mahfoud F.

J Hypertens. 2015 Dec;33(12):2519-25.

Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP).
http://www.ncbi.nlm.nih.gov/pubmed/26456786

Meyer MR, Holderbaum A, Kavanagh P, Maurer HH.

J Mass Spectrom. 2015 Oct;50(10):1163-74.

Prevalence and distribution patterns of amphetamine and methamphetamine consumption in a federal state in southwestern Germany using wastewater analysis.
http://www.ncbi.nlm.nih.gov/pubmed/26416694

Meyer MR, Vollerthun T, Hasselbach R.

Drug Alcohol Depend. 2015 Nov 1;156:311-4.

Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - Exemplified for cardiovascular drugs.
http://www.ncbi.nlm.nih.gov/pubmed/26388381

Helfer AG, Michely JA, Weber AA, Meyer MR, Maurer HH.

Anal Chim Acta. 2015 Sep 3;891:221-33.

First report on the pharmacokinetics of tramadol and O-desmethyltramadol in exhaled breath compared to plasma and oral fluid after a single oral dose.
http://www.ncbi.nlm.nih.gov/pubmed/26388171

Meyer MR, Rosenborg S, Stenberg M, Beck O.

Biochem Pharmacol. 2015 Dec 1;98(3):502-10.

Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis.
http://www.ncbi.nlm.nih.gov/pubmed/26306594

Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, Maurer HH, Böhm M, Mahfoud F.

Clin Res Cardiol. 2015 Dec;104(12):1097-105.

Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MS (n) , and LC-HR-MS-MS.
http://www.ncbi.nlm.nih.gov/pubmed/26297461

Michely JA, Helfer AG, Brandt SD, Meyer MR, Maurer HH.

Anal Bioanal Chem. 2015 Oct;407(25):7831-42.

Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps.
http://www.ncbi.nlm.nih.gov/pubmed/26276083

Wink CS, Meyer GM, Meyer MR, Maurer HH.

Toxicol Lett. 2015 Nov 4;238(3):39-44.

Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?
http://www.ncbi.nlm.nih.gov/pubmed/26538506

Billat PA, Woillard JB, Essig M, Sauvage FL, Picard N, Alain S, Neely M, Marquet P, Saint-Marcoux F.

J Antimicrob Chemother. 2016 Feb;71(2):484-9. Epub 2015 Nov 3.

Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs.
http://www.ncbi.nlm.nih.gov/pubmed/26469711

Picard N, Bergan S, Marquet P, van Gelder T, Wallemacq P, Hesselink DA, Haufroid V.

Ther Drug Monit. 2016 Apr;38 Suppl 1:S57-69. Epub 2015 Oct 13.

Analytical aspects of the implementation of biomarkers in clinical transplantation.
http://www.ncbi.nlm.nih.gov/pubmed/26418704

Shipkova M, López OM, Picard N, Noceti O, Sommerer C, Christians U, Wieland E.

Ther Drug Monit. 2016 Apr;38 Suppl 1:S80-92. Epub 2015 Jul 30.

Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.
http://www.ncbi.nlm.nih.gov/pubmed/26237184

Hareedy MS, El Desoky ES, Woillard JB, Thabet RH, Ali AM, Marquet P, Picard N.

Pharmacogenomics. 2015;16(10):1119-34.

Genetic polymorphisms in the immune response: A focus on kidney transplantation.
http://www.ncbi.nlm.nih.gov/pubmed/26171975

Stojanova J, Pouché L, Picard N.

Clin Biochem. 2016 Mar;49(4-5):363-76. Epub 2015 Jul 11.

The Area Under the Concentration-Time Curve Is a Better Estimate for Vancomycin Exposure Than Trough Levels.
http://www.ncbi.nlm.nih.gov/pubmed/26274735

van Vessem DJ, Juffermans NP, Bouman CS, van Hest RM.

Crit Care Med. 2015 Sep;43(9):e401.

A cluster randomized trial for the implementation of an antibiotic checklist based on validated quality indicators: the AB-checklist.
http://www.ncbi.nlm.nih.gov/pubmed/25888180

van Daalen FV, Prins JM, Opmeer BC, Boermeester MA, Visser CE, van Hest RM, Hulscher ME, Geerlings SE.

BMC Infect Dis. 2015 Mar 19;15:134.

Is gentamicin affecting the neuromuscular system of critically ill patients?
http://www.ncbi.nlm.nih.gov/pubmed/25752304

Wieske L, van Hest RM, Witteveen E, Verhamme C, Schultz MJ, van Schaik IN, Horn J.

J Intensive Care Med. 2015 Apr;41(4):727-8.

A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.
http://www.ncbi.nlm.nih.gov/pubmed/25480313

Khorsand N, Kooistra HA, van Hest RM, Veeger NJ, Meijer K.

Thromb Res. 2015 Jan;135(1):9-19.

Quantification of phosphatidylethanol 16:0/18:1, 18:1/18:1, and 16:0/16:0 in venous blood and venous and capillary dried blood spots from patients in alcohol withdrawal and control volunteers.
http://www.ncbi.nlm.nih.gov/pubmed/26597914

Kummer N, Ingels AS, Wille SM, Hanak C, Verbanck P, Lambert WE, Samyn N, Stove CP.

Anal Bioanal Chem. 2016 Jan;408(3):825-38. Epub 2015 Nov 23.

Detection of Benzodiazepines and z-Drugs in Hair Using an UHPLC-MS/MS Validated Method: Application to Workplace Drug Testing.
http://www.ncbi.nlm.nih.gov/pubmed/25627407

Ramírez Fernández Mdel M, Wille SM, di Fazio V, Kummer N, Hill V, Samyn N.

Ther Drug Monit. 2015 Oct;37(5):600-8

Applications of oral fluid and dried blood spots as a matrix for roadside drug testing.
Wille SM, Ingels A., Samyn N.

Bioanalysis. E-Book Chapter 7; New Sampling strategies in Toxicology and Therapeutic Drug Monitoring 2015

ISBN: 978-1-910420-09-6 (print)

2014

Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography-linear ion-trap (high-resolution) mass spectrometry.
http://www.ncbi.nlm.nih.gov/pubmed/24448968

Meyer MR, Lindauer C, Welter J, Maurer HH

Anal Bioanal Chem. 2014;406(7):1845-54

IATDMCT Young Scientists please contact the YSC with details of your author publications for the current year.

contactus273x169

Contact Us

Scientific Committees
Young Scientist Committee